Kamata K - Search Results

1

Kawahara K, Kamata K. Kawahara K, et al. Among authors: kamata k. Clin Exp Nephrol. 2012 Feb;16(1):3-7. doi: 10.1007/s10157-012-0597-3. Clin Exp Nephrol. 2012. PMID: 22350462 No abstract available.

2

Spontaneous rupture of a left gastroepiploic artery aneurysm in a patient with autosomal-dominant polycystic kidney disease.

Nagaba Y, Nishimaki H, Ichinoe M, Okuwaki Y, Hamura M, Makino T, Sano T, Higashihara M, Kamata K, Soma K. Nagaba Y, et al. Among authors: kamata k. Clin Nephrol. 2005 Feb;63(2):163-6. doi: 10.5414/cnp63163. Clin Nephrol. 2005. PMID: 15730059

3

Antigen-binding abilities of anti-nephrin antibody are prescribed by signal sequence of expression vector in genetic immunization.

Naito S, Kamata K, Aoyama T, Yamanaka N, Okamoto T, Tazaki H. Naito S, et al. Among authors: kamata k. Clin Exp Nephrol. 2011 Jun;15(3):339-345. doi: 10.1007/s10157-010-0399-4. Epub 2011 Jan 29. Clin Exp Nephrol. 2011. PMID: 21279413

4

Compositional similarity between immunoglobulins binding to asialo-, agalacto-IgA1-Sepharose and those deposited in glomeruli in IgA nephropathy.

Takatani T, Iwase H, Itoh A, Nakamura I, Hayashi M, Sakamoto H, Kamata K, Kobayashi Y, Hiki Y, Okamoto M, Higashihara M. Takatani T, et al. Among authors: kamata k. J Nephrol. 2004 Sep-Oct;17(5):679-86. J Nephrol. 2004. PMID: 15593035

5

[Definition, diagnosis, grading and treatment of chronic kidney disease (CKD): an update].

Kamata K. Kamata K. Masui. 2013 Nov;62(11):1284-92. Masui. 2013. PMID: 24364269 Review. Japanese.

6

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators. Higashihara E, et al. Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8. Clin J Am Soc Nephrol. 2011. PMID: 21903984 Free PMC article. Clinical Trial.

7

Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy.

Oshikawa J, Toya Y, Morita S, Taguri M, Hanaoka K, Hasegawa T, Kaizu K, Kamata K, Kobayashi S, Ohtake T, Sato T, Yasuda G, Kimura K, Umemura S. Oshikawa J, et al. Among authors: kamata k. Clin Exp Hypertens. 2014;36(4):244-50. doi: 10.3109/10641963.2013.810227. Epub 2013 Jul 12. Clin Exp Hypertens. 2014. PMID: 23848219 Clinical Trial.

8

Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).

Yasuda T, Endoh M, Suzuki D, Yoshimura A, Ideura T, Tamura K, Kamata K, Toya Y, Umemura S, Kimura K; KVT Study Group. Yasuda T, et al. Among authors: kamata k. Hypertens Res. 2013 Mar;36(3):240-6. doi: 10.1038/hr.2012.183. Epub 2012 Nov 15. Hypertens Res. 2013. PMID: 23154591 Clinical Trial.

9

Characteristics of heart rate variability entropy and blood pressure during hemodialysis in patients with end-stage renal disease.

Yamanaka N, Aoyama T, Ikeda N, Higashihara M, Kamata K. Yamanaka N, et al. Among authors: kamata k. Hemodial Int. 2005 Jul;9(3):303-8. doi: 10.1111/j.1492-7535.2005.01145.x. Hemodial Int. 2005. PMID: 16191081

10

A possible clue for the production of anti-glomerular basement membrane antibody associated with ureteral obstruction and hydronephrosis.

Takeuchi Y, Takeuchi E, Kamata K. Takeuchi Y, et al. Among authors: kamata k. Case Rep Nephrol Dial. 2015 Mar 31;5(1):87-95. doi: 10.1159/000381396. eCollection 2015 Jan-Apr. Case Rep Nephrol Dial. 2015. PMID: 25960997 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

993 results

Search Page